CO-WESTERN-UNION
The Western Union Foundation today announced its first-quarter 2021 programs, investing more than USD 1.25 million to mobilize youth to access jobs in the healthcare industry, assisting with COVID-19 vaccine education and distribution, and to enable economic recovery through workforce training. This investment furthers the Western Union Foundation’s Opportunity Beyond Borders three-year USD 15 million commitment to provide migrant and young adults with resources to gain sustainable employment and provide relief and preparedness for crises.
“The Western Union Foundation recognizes that this moment—as the global pandemic recovery effort begins in earnest—is a crucial one for the communities we serve,” said Foundation Executive Director Elizabeth Roscoe. “We are determined to do everything we can to keep people who are already on the margins from falling farther behind because they lack access to vaccines or opportunities to participate in the formal labor markets as economies progress toward recovery.”
In 2020, the first full year of Opportunity Beyond Borders, the Western Union Foundation invested more than USD 6 million to help 200,000 people in 33 countries, as detailed in its 2020 Global Impact Report .
COVID-19 vaccine education, preparedness, and distribution programs
Research has shown a large portion of the population in many low-income countries is hesitant to get the vaccine, often due to lack of education about the vaccine and logistical challenges to reach vaccine centers. The Aspen Institute and International Medical Corps will receive funds from the Western Union Foundation to address these challenges.
In Kenya and India , the Aspen Institute will partner with leading community-based organizations to support vaccine education and distribution efforts by skilling youth and women in the community in vaccine awareness, preparedness and access.
In the Philippines , the International Medical Corps program will address vaccine hesitancy by driving awareness and coordinating transportation for vulnerable populations to vaccine centers.
In Pakistan , host to the third-largest number of refugees in the world , International Medical Corps will train volunteers in refugee villages to raise vaccine awareness and promote health and hygiene best practices.
Western Union and the Foundation are further enabling vaccine adoption by donating funds on behalf of each vaccinated Western Union employee and allowing employees to donate directly to the cause. This program will provide up to $350K to help inoculate thousands more in rural communities.
Workforce training for entrepreneurship and career pathways
In addition to the COVID-19 community resilience programs, the Foundation’s first-quarter investment aims to enable economic recovery for migrant and refugee communities affected by last year’s lockdowns. The following are a few of the programs:
In Mexico , the Whitaker Peace & Development Initiative will scale entrepreneurship programs by training young business leaders and incubating micro-businesses that provide essential services and products to their local communities.
In Jordan and Lebanon , the Kiron Open Higher Education program will work with the most vulnerable populations residing in refugee encampments and will offer skill-building opportunities to prepare individuals for and give access to career pathways.
In Jordan and Palestine , Education for Employment will launch a research study about relevant jobs post-COVID-19 and provide customized training to business owners, with the majority female, helping them adapt and grow their businesses in response to the effects of COVID-19.
To learn more about the impact the Western Union Foundation has made to people and partners over the past year, check out the stories of impact on their newly launched website .
About the Western Union Foundation
The Western Union Foundation believes that education is the surest pathway to economic opportunity. After 20 years of impact, we continue to deliver on our mission with Opportunity Beyond Borders, focused on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. The Foundation also provides funding for humanitarian efforts for communities in crisis and disaster, one key reason for forced migration. To date, we have funded more than $131 million for projects and scholarships. The Western Union Foundation is a separate, tax-exempt 501(c)(3) charitable corporation and receives support from The Western Union Company, its employees, agents, and business partners. Contributions to the Foundation are tax-deductible for U.S. income tax purposes. To learn more, visit www.westernunionfoundation.org or follow us on Twitter @TheWUFoundation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005454/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
